+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of perfusion-guided endovascular treatment EVT compared to standard medical care for adults who have had an acute ischemic stroke caused by medium vessel occlusion within 24 hours of symptom onset. This study focuses on patients with specific artery blockages confirmed by imaging and a baseline stroke severity score of 8 or higher. The goal is to see how well patients recover by measuring their ability to function independently 90 days after treatment. Participants will be randomly assigned to one of two groups one receiving endovascular treatment plus best medical treatment, and the other receiving best medical treatment alone. The endovascular treatment involves techniques such as thrombectomy, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or combinations of these, performed immediately after randomization. Best medical treatment follows current clinical guidelines and is administered independently of the study treatment. During the study, participants will undergo neuroimaging to confirm eligibility and will be monitored regularly for neurological improvement, safety events, and overall recovery using scales like the modified Rankin Scale at 90 days and one year. Researchers will collect data on stroke severity, quality of life, bleeding complications, and mortality. The study starts in February 2026 and continues until September 2028, with participant follow-up lasting at least one year after treatment.

Age: 18Years +All GendersPhase Not Applicable
6 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of different doses of Anakinra compared to standard medical care in adults who have had an acute ischemic stroke and successful recanalization through endovascular thrombectomy. This phase 2, multicenter, randomized, open-label trial focuses on patients with stroke caused by blockage in key arteries confirmed by imaging, with a specific range of stroke severity scores. Participants will be randomly assigned to one of three groups high-dose Anakinra with a loading dose followed by continuous infusion, low-dose Anakinra with a loading dose followed by twice-daily injections, or standard medical treatment as per guidelines. Treatments begin within 30 minutes after randomization, and standard care is provided alongside the investigational interventions. Throughout the study, participants will undergo MRI scans to measure changes in brain injury size within 5 to 7 days. Additional assessments include neurological scales at various time points, evaluation of functional outcomes at 90 days, and monitoring for safety events. The total study duration includes treatment and follow-up periods, with the primary focus on reducing stroke damage and improving recovery.

Age: 18Years - 80YearsAll GendersPhase 2
6 locations